Biotivia, a world leading developer of resveratrol based products, has launched PteroMax, a unique formulation containing the rare stilbene polydatin plus a blend of pterostilbene, resveratrol, concentrated fruit polyphenols, and OPC oligometric proanthocyanadins from Green tea.
Polydatin, also known to medical researchers as piceid, is a glucoside of resveratrol. This means that the resveratrol is joined to a sugar molecule. Once the polydatin enters the bloodstream the sugar molecule is cleaved off, leaving the resveratrol. This in turn means that the glucoside of resveratrol is absorbed at a different rate to standard trans-resveratrol, thereby effectively increasing the half-life and the potency of the resveratrol.
James Betz, CEO of Biotivia, said: "We put a lot of effort into researching the optimum blend of stilbenes and other molecules in PteroMax to produce a potent supplement that is both synergistic and highly bio-available. By combining the three principal analogs of resveratrol we have created an extraordinary potent full spectrum stilbene formulation"
The PteroMax formulation contains 100mg of 98% trans-polydatin, 100mg of 98% trans-pterostilbene, 250mg of 50% trans-resveratrol and 100mg of wide-spectrum OPC oligometric proanthocyanadins and polyphenols.
To read more about PteroMax please visit http://www.biotivia.com/polydatin.html
About Biotivia LLC
Biotivia was established in 1992 in Vienna, Austria as a supplier of natural raw materials and biologically active botanics to the supplement and functional food industries and to researchers and scientific institutions worldwide. The company evolved into one of the world's leading developers and suppliers of unique science-based nutritional supplements and award winning skin care therapies, with most of their products centered around the use of concentrated resveratrol and complementary botanical extracts.
Biotivia presently has US offices in New York, Los Angeles, Kansas City and international offices in the UK, Spain, Austria, Denmark, Italy, Germany, Singapore, Xi'an, China and Mumbai, India.
Beyond its strong consumer base, the company currently supplies researchers, physicians and scientists at Harvard, Stanford, Yale, Georgetown, The Albert Einstein Medical Center, University of Texas, M.D. Anderson Cancer Center, Health Canada, and the University of California. Transmax and Bioforte in particular are being investigated by several major university medical schools as a possible treatment for a variety of conditions that seriously impair the health and well being of millions of people around the world. Biotivia most recently signed an agreement to supply Transmax to the University of Ferrara for use in three human clinical trials in Italy and Egypt on its possible use by Thalassemia sufferers as an alternative to the whole blood transfusions which such patients now require monthly. The Albert Einstein Medical College published a study which elucidated the beneficial effects of Biotivia's proprietary resveratrol on glucose tolerance and mitochondria function in pre-diabetic subjects. Bioforte was also shown to more than double brain blood flow in a study done at the University of Northumbria in the UK.
Biotivia's resveratrol products, Transmax and Bioforte, have been independently assessed by Consumer Labs, the leading American quality watchdog, and were deemed both 'most potent' and 'best value'. Transmax has been certified as an investigational drug by the NIH, an endorsement of its safety and purity.
Most of Biotivia's supplements have been certified Vegan by the American Vegetarian Association.
Important Caveat: Neither PteroMax nor any Biotivia product has been definitively shown to diagnose, prevent or cure any age related diseases. PteroMax is not intended to diagnose, prevent, treat or cure any disease. Studies done in vitro and on animals do not always translate into the same biological effect when taken by human subjects. The statements herein have not been reviewed or approved by the US FDA. All Biotivia supplements are manufactured in state of the art government inspected pharmaceutical facilities in accordance with CGMP and USP standards.